StocksFin Logo
Ironwood Pharmaceuticals, Inc. country of incorporation
|
|
Mr. Mark Mallon
|
219 employees
NASDAQ | Healthcare | Drug Manufacturers—Specialty & Generic
NASDAQ | Healthcare | Medical Devices
Q322 reported Nov 3, 2022 Reporting Period
$108.64M 4.7% vs. Q321 Revenues Q322
0% -100% vs. Q321 Gross Profit Margin
46.32% -14% vs. Q321 Net Profit Margin
69.03M -8% vs. Q321 Free Cash Flow Q322
$0.33 -2.9% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Q322 reported Nov 4, 2022 Reporting Period
$20.35M 134.8% vs. Q321 Revenues Q322
50.28% 2.8% vs. Q321 Gross Profit Margin
-111.13% ! 31.7% vs. Q321 Net Profit Margin
-21.37M ! -67.6% vs. Q321 Free Cash Flow Q322
$-0.51 ! 58.2% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
25.47
9.58
Current Ratio
25.78
10.56
Cash Ratio
21.17
9.11
Price to Book
2.68
8.38
Price to Sales
14.6
90.95
Price to Earnings
7.88
-20.46